Is TRIB a good growth

**Trinity Biotech's growth trajectory appears to be mixed, with some positive developments but also notable challenges.** Here's an analysis based on the available data: 1. **Revenue Growth**: The company's total revenue has shown a decline over the past three years, with a quarterly growth rate of -11.27% in Q4 2021, -7.52% in Q4 2022, and -8.51% in Q1 2023. This indicates a consistent downward trend in revenue. |Ticker|Name|Total Revenue QoQ growth rate|Date|code|market_code| |---|---|---|---|---|---| |TRIB.O|Trinity Biotech|-11.266133430285402|20211231|TRIB|185| |TRIB.O|Trinity Biotech|-7.517177725361501|20221231|TRIB|185| |TRIB.O|Trinity Biotech|-8.509913470055189|20231231|TRIB|185| 2. **Net Income Growth**: The net income growth rate has also been volatile, with a significant decline of -195.69% in Q1 2022, followed by a recovery with an 18.14% growth rate in Q4 2023. This suggests that while the company has made some improvements in net income, it has not been consistent. |Ticker|Name|Net Income QoQ growth rate|Date|code|market_code| |---|---|---|---|---|---| |TRIB.O|Trinity Biotech|-195.68508705526116|20211231|TRIB|185| |TRIB.O|Trinity Biotech|-12.688652878703186|20221231|TRIB|185| |TRIB.O|Trinity Biotech|18.1371819669692|20231231|TRIB|185| 3. **Analyst Ratings and Estimates**: Analysts have not provided specific EPS or revenue estimates for the current or upcoming quarters or years. However, the consensus estimate for the current full-year earnings is negative, with Trinity Biotech expected to post an EPS of ($2.17) per share. 4. **Stock Performance**: Despite the negative growth metrics, the stock has seen a significant gain of 34% in the last month. This could be due to market sentiment or strategic developments that investors find promising. 5. **Strategic Developments**: The company's attendance at industry events, such as the 84th Scientific Sessions of the American Diabetes Association, and the initiation of coverage by analysts at StockNews.com with a "buy" rating, indicate ongoing efforts to engage with stakeholders and potential partners. 6. **Research and Development**: There has been an increase in research and development expenses, which could be a positive sign as it may lead to new product development and innovation. In conclusion, while TRIB has shown some positive signs, such as strategic developments and increased R&D investment, the consistent decline in revenue over the past three years and the negative net income growth rate in the recent past raise concerns about its growth prospects. Investors should carefully consider these factors before making an investment decision.